HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Church & Dwight Takes Homeopathic Turn For OTC Sales Driver, Acquires Zicam Marketer Matrixx

Executive Summary

C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.

You may also be interested in...



Church & Dwight: Pregnancy Test Sales Show Consumer Confidence Strong Despite Pandemic

First Response pregnancy test sales didn’t decline during the pandemic as the underlying strength of the economy doesn’t slow consumer interest in expanding their families, says Church & Dwight CEO Matthew Farrell.

Top 20 Consumer Health Deals 2020: Private Equity And OTC Exits Drive M&A

HBW Insight reveals the biggest consumer health deals of 2020, and identifies growing private equity investment, portfolio streamlining by major players and pharma firms exiting OTC as the major drivers of M&A activity.

Church & Dwight Lifts Curtain On 2021: Halle Berry For Flawless, Vitafusion In Cough/Cold Aisle

Emerging markets expected to be growth drivers across C&D’s supplement, OTC drug and household care product lines in 2021. Super Immune formulation with more than 100% daily value of vitamin C, zinc and elderberry and Manuka honey is first vitafusion product in cough/cold aisle and brand's first extension for 2021.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS150757

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel